Home Biosimilar Antibodies Others Others Ravulizumab (Anti-Complement C5)
For research use only. Not for use in humans.

Ravulizumab (Anti-Complement C5)

Synonyms: ALXN1210

Ravulizumab (Anti-Complement C5) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. MW: 145.5 KD.

Ravulizumab (Anti-Complement C5)

Quality Control

Batch: A253701 Purity: 99% Protein concentration: 8.63mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Ravulizumab (Anti-Complement C5) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. MW: 145.5 KD.

Product Details

CAS No. 1803171-55-2
Molecular Weight 145.5 kDa
Isotype Human IgG2SA
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.